Published

Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in Human Neuroscience
Date: 2023-07-17
Source: OpenAlex
DOI: 10.3389/fnhum.2023.1200393
PubMed: 37533588

Authors

Nicolas Garel Julien Thibault Lévesque Dasha A. Sandra Justin Lessard-Wajcer Elizaveta Solomonova Michael Lifshitz Stéphane Richard-Devantoy Kyle T. Greenway

Watch author

Derived topics and classifications

psilocybin Depression Mechanism of Action Receptor Pharmacology Emotional Processing Mystical Experience Clinical Trial Review Article Treatment-Resistant Depression Healthcare Workers Toxicity Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings2023-07-17

Related papers

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of ConsciousnessClinicalTrials.gov · 2023-03-29 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10